New Publication from IMPACT Trial: Efficacy and safety of oral immunotherapy in children aged 1–3 years with peanut allergy

The IMPACT trial – a double blind randomized placebo controlled study – was designed to test whether young, peanut allergic children (12-48 months) could be desensitized with peanut oral immunotherapy (OIT) and ultimately remain non-responsive to peanut after discontinuation of OIT.